Radiation-induced apoptosis is thought to underlie the toxicity of radiation to normal tissues as well as to cancer cells. We hypothesized that specific ectopic overexpression of the antiapoptotic molecule Bcl-2 in normal cells would inhibit radiationinduced apoptosis and thereby reduce radiation-induced toxicity in normal cells. To express Bcl-2 specifically in normal cells (which have wild-type (wt) p53) but not in cancer cells (which often have mutated p53), we constructed a Bcl-2 expression plasmid (PG 13 -Bcl-2) with a minimal promoter regulated by multiple wt p53 DNA-binding sites and found that the presence of wt p53 protein strongly upregulated Bcl-2 expression through this plasmid. Transfection of NIH 3T3 fibroblasts, which express wt p53, with PG 13 -Bcl-2 increased cell survival and reduced apoptosis; however, transfection of MDA-MB-231 breast cancer cells, which have mutated p53, did not affect survival and apoptosis of those cells. These results indicate that irradiation of normal cells rapidly upregulates the expression of wt p53, which binds to the p53 binding sequence of the PG 13 -Bcl-2 plasmid and increases the transcriptional activity of Bcl-2. Ectopic expression of Bcl-2 reduced radiation-induced apoptosis only in normal cells (not in cancer cells). Bcl-2 expression was detected in the lung from mice injected via a tail vein with LPD-PG 13 -Bcl-2 or LPD-CMV-Bcl-2, but did not in the lung from mice treated with DOTAP or LPD-PG 13 -mock. This novel approach to inhibiting radiation-induced apoptosis in normal cells may allow such cells to be protected from radiation-induced toxicity. Further preclinical in vivo studies are needed.
Introduction
Ionizing radiation has been used to treat a variety of types of cancer in humans. However, the maximum dose of radiation that can be delivered in such treatments is limited by the tolerance of the surrounding normal tissues, which in turn is thought to result from apoptosis of the normal tissue cells. Whole-body irradiation, for example, results in increased apoptosis of endothelial cells and can trigger gastrointestinal syndrome 1 or central nervous system injury. 2 Deng et al. 3 reported that excessive epithelial apoptosis is one of the main etiological factors that contributes gastrointestinal syndrome following irradiation. Our long-term goal in this project was to develop a therapeutic gene with which to prevent radiation-induced toxicity in normal cells by reducing apoptosis.
One candidate gene being evaluated for this purpose is Bcl-2, the product of which is the best characterized member of a family of proteins that inhibit apoptosis. 4 Bcl-2 encodes a 26-kDa integral membrane protein that resides primarily in the outer mitochondrial membrane, nuclear envelope, and parts of the endoplasmic reticulum. 5 Forced expression of the Bcl-2 gene has been shown to abrogate or delay apoptosis in numerous experimental systems in response to diverse apoptotic stimuli such as chemotherapeutic drugs, 4 g-irradiation, 6,7 growth factor deprivation and glucocorticoids, 6 and lytic infection. 8 Expression of Bcl-2 by cancer cells, however, may confer resistance to drugs or radiation, 9 and thus some means of distinguishing normal from cancerous cells is needed to protect the former but not the latter.
The p53 tumor suppressor pathway is a pivotal mediator of genotoxic stress responses. Mutations or deletions in the p53 gene are the most common genetic changes in human cancer and predict poor response to chemotherapy 10 and poor prognosis. 11 p53 mutations have been reported in up to half of all human tumors. 12 Reasoning that p53 status could be exploited to distinguish normal cells (which express wild-type (wt) p53) from cancer cells (which express mutated forms of p53), we sought to induce the wt p53-specific expression of the antiapoptotic molecule Bcl-2 in normal cells without increasing its expression in cancer cells, with the goal of protecting normal cells -but not cancer cells -from radiation-induced apoptosis. To restrict Bcl-2 expression to normal cells, we constructed a Bcl-2 expression plasmid (PG 13 -Bcl-2) with a minimal promoter regulated by multiple p53-DNA-binding sites upstream of the Bcl-2 gene, 13 used this plasmid to transfect NIH 3T3 normal mouse fibroblasts and MDA-MB-231 human breast cancer cells, and compared their expression of Bcl-2 and apoptosis after irradiation. Our hypothesis was that induction of Bcl-2 expression by a p53-inducible promoter would reduce radiation-induced apoptosis in normal cells but not in cancer cells.
Materials and methods

Cell cultures and transfections
The human breast cancer cell line MDA-MB-231, mouse fibroblast cell line NIH 3T3, and lung cancer cell line H1299 were obtained from American Type Culture Collection (Manassas, VA). Cells were grown in DMEM/F12 medium (GIBCO, Grand Island, NY) supplemented with 10% fetal bovine serum and penicillin/ streptomycin and maintained at 371C in a humidified incubator with 5% CO 2 . Both types of cells were transfected with a pCl-neo/Bcl-2 (CMV-Bcl-2) plasmid encoding for the Bcl-2 proto-oncogene and the neomycinresistance gene (generously provided by Dr Michael Andreeff, MD Anderson Cancer Center, Houston, TX) or with a control pCl-neo plasmid by using FuGENE 6 Transfection Reagent (Roche Molecular Biochemicals, Indianapolis, IN). Neomycin selection was initiated 48 h after transfection in medium containing 400 mg/ml G418 (GIBCO), and selected G418-resistant colonies were cloned and expanded into cell lines.
Construction of Bcl-2 expression plasmids
The PG 13 Luc plasmid, which contains the polyomavirus early promotor and the luciferase (Luc) gene located downstream of a DNA sequence (PG) that binds wt p53 in vitro, was the kind gift of Dr Wafik El-Deiry (Howard Hughes Medical Institute, Philadelphia, PA). 13 We extracted the PG 13 vector as Spe1/Xba1 fragments from the PG 13 Luc plasmid; full-length Bcl-2 was obtained from the CMV-Bcl-2 plasmid and subcloned into the PG 13 vector (Figure 3a) .
Western blot analysis
To extract proteins, cells were washed three times with ice-cold PBS and lysed in lysis buffer, after which 20 mg of protein was separated by 10% SDS-PAGE and transferred to polyvinylidene difluoride membranes (Millipore Co., Bedford, MA). Nonspecific binding on those membranes was minimized by using a blocking buffer containing 5% nonfat dry milk and 0.1% v/v Tween 20 in PBS, after which the membranes were incubated with antibodies specific for murine p53 (Santa Cruz Biotechnology Inc., Santa Cruz, CA), human p53 (Oncogene, Boston, MA), Bcl-2 (PharMingen, San Diego, CA), and b-actin (Sigma Chemical Co., St Louis, MO) for overnight at 41C. The membranes were then incubated with horseradish peroxidase-conjugated secondary antibody for 1 h at room temperature, and protein signals were detected by enhanced chemiluminescence (Amersham, Buckinghamshire, UK). The relative intensity of the immunoblots was quantified with the NIH Image program (available at http://rsb.info.nih.gov/nih-image/ Default.html).
Sensitivity to irradiation
Radiation sensitivity was determined by using a 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay.
14 Briefly, cells were diluted with culture medium to a seeding density of 3 Â 10 4 cells/ml, suspended in 96-well tissue culture plates (100 ml/well), and incubated overnight at 371C. Cells were then exposed to a single dose of radiation with a Nasatron Cesium-137 irradiator at room temperature. After incubation for 72 h, 10 ml of MTT solution (5 mg/ml) (Sigma Chemical Co., St Louis, MO) was added to each well, and the plates were incubated for another 4 h. At that time, 100 ml of dimethylsulfoxide was added to solubilize the MTT formazan product. Absorbance at 570 nm was measured with a Benchmark Microplate Reader (Bio-Rad, Hercules, CA).
Flow cytometric analysis of cell cycle status and apoptosis For these analyses, cells were trypsinized, washed with PBS, fixed with 70% ethanol, and kept at À201C at least overnight. Before analysis, cells were washed with PBS and resuspended in PBS containing 40 mg/ml propidium iodide (Sigma) and 250 mg/ml RNase (Sigma). After a 30-min incubation at 371C, the cells were then analyzed with a FACScan cytofluorometer (Becton Dickinson, San Jose, CA).
Apoptosis assessment by annexin v staining
Phosphatidylserine residues were detected with the Annexin V-PE Apoptosis Detection Kit I (BD Biosciences Pharmingen, San Diego, CA) according to the manufacturer's specifications. The green fluorescence protein (GFP; p-EGFP-N1, Clontech, Basingstoke, UK) and apoptosis markers were detected with a FACScan cytofluorometer.
Clonogenic assay
To determine their radiosensitivity, we plated parental MDA-MB-231 and NIH 3T3 cells, and their Bcl-2-expressing transfectants, in six-well plates at a density of 1000 cells/well and allowed them to adhere overnight. Cells were then exposed to 1-10 Gy of radiation. After 24 h, cells were plated in 6 cm dishes in fresh medium (1000 cells/well) and colonies were counted 10-14 days later after staining with crystal violet (Sigma).
Mice and irradiation
Female NCR/Sed-nu/ þ (NCR) mice, bred and maintained in a specific pathogen-free colony, were used. They were housed five to a cage and were given sterilized food and sterilized acidified water in an animal colony approved by the American Association for Accreditation of Laboratory Animal Care and in accordance with current regulations and standards of the United States Department of Agriculture and Department of Health and Human Services, National Institutes of Health. The mice, 2-3 months old, were received the whole body irradiation doses of 10 Gy. Groups of four unanesthetized mice were irradiated simultaneously through a ventral portal using a Phillips 250-kVp X-ray unit at a setting of 250 kVp, 15 mA at 80% output, with a skin surface distance of 35.5 cm and a half-value layer of 0.5 mm Cu. The dose rate was 1.05 Gy/min. At 24 h before irradiation, mice were injected via a tail vein with DOTAPcholesterol-protamine sulfate-DNA complex (LPD; Avanti Polar Lipids Inc., Alabaster, AL)-PG 13 -mock, LPD-PG 13 -Bcl-2, or LPD-CMV-Bcl-2 (20 mg DNA).
Immunohistochemistry
The mice were euthanized 24 h after irradiation and then lungs were harvested, fixed in 10% formalin and paraffin embedded. Routine 4-mm paraffin sections were prepared. Deparaffinized sections were heated for 15 min in citrate buffer (DakoCytomation Inc., Carpinteria, CA) in a microwave oven for antigen retrieval. The primary antibody used was human anti-Bcl-2 (Santa Cruz Biothecnology, Inc., Santa Cruz, CA). The sections were then immunostained using the VECTASTAIN Elite ABC KIT (Vector laboratories Inc., Burlingame, CA) followed by a weak hematoxylin counterstain.
Statistical analysis
Statistical analyses were performed using Version 5J of the JMP program (SAS Institute, Cary, NC). Data are presented as means71 s.d. Means for all data were compared by one-way analysis of variance with post hoc testing. P values o0.05 were considered to indicate statistical significance.
Results
Overexpression of Bcl-2 reduced radiation-induced cytotoxicity in both normal and cancer cells To determine if ectopic expression of Bcl-2 could inhibit radiation-induced cytotoxicity, we transfected MDA-MB-231 breast cancer cells and NIH 3T3 normal mouse fibroblasts to make them constitutively express Bcl-2 and tested the protein expression of individual clones by Western blotting. Transfectant clones of both cell lines expressed higher levels of Bcl-2 protein than did the parental or neomycin control cells (Figure 1a) .
We then used an MTT assay to examine the effect of Bcl-2 overexpression on cell survival after a single dose of ionizing radiation (10, 20, or 40 Gy for MDA-MB-231 cells, or 10 or 20 Gy for NIH 3T3 cells). At 72 h after irradiation, more of the Bcl-2-expressing clones (in both cell lines) had survived than the parental or neo control cells (Po0.01) (Figure 1b) .
To investigate whether expression of Bcl-2 increased cell survival through inhibiting apoptosis, we assessed the proportions of apoptotic cells by FACS after irradiation. At 96 h after irradiation, fewer Bcl-2-overexpressing cells were apoptotic than the parental or neo control cells (Figure 1c and d) , indicating that ectopic overexpression of Bcl-2 reduced radiation-induced cytotoxicity in both normal and cancer cells.
To evaluate long-term survival of cells after exposure to various doses of ionizing radiation, we examined the clonogenic survival of parental cells (MDA-MB-231 and NIH 3T3), neo control transfectants, and Bcl-2 transfectant clones. Most cells lost the ability to form colonies after a radiation dose of 1-10 Gy, and this effect was dose-dependent ( Figure 2 ). Clonogenic survival was significantly increased in the Bcl-2-expressing clones (by a factor of about two for the MDA-MB-231 cells and by a factor of four for NIH 3T3 cells) compared with the parental or neo control cells after a single radiation dose of 2 Gy (Po0.05).
PG 13 -Bcl-2 Plasmids Protect Normal Cells from Radiation-Induced Cytotoxicity As Bcl-2 reduced apoptosis and cytotoxicity both in normal cells and cancer cells, our next step was to prevent Bcl-2 from being expressed in the cancer cells. We used p53 status to distinguish normal cells (normal (wt) p53) from cancer cells (p53 mutation or deletion). We constructed PG 13 -Bcl-2 plasmids containing Bcl-2 cDNA under the control of a minimal promoter regulated by 13 copies of the DNA sequence that binds wt p53 (Figure 3a) .
We first tested whether wt p53 could induce Bcl-2 protein expression by cotransfecting these two molecules into H1299 lung cancer cells, which have a homozygous deletion of the p53 gene. Transfection of these cells with PG 13 -Bcl-2 and wt p53 (generously provided by Dr MC Hung, M.D. Anderson Cancer Center, Houston, TX) plasmids led to upregulation of Bcl-2 expression, but only in cells transfected with both PG 13 -Bcl-2 and wt p53 (Figure 3b ). These findings suggest that wt p53 activates Bcl-2 gene expression in vitro by binding to the PG multimer.
Our next step involved testing whether radiationinduced wt p53 could activate Bcl-2 delivered by means of a PG 13 -Bcl-2 plasmid. In these experiments, MDA-MB-231 cells and NIH 3T3 cells were transfected with PG 13 -mock or PG 13 Finally, to examine whether the increase in Bcl-2 expression level translated into an increase in cell survival, we transfected MDA-MB-231 cells and NIH 3T3 cells with luciferase plasmid (pGL3-Promoter Vector, Promega, Madison, WI) and PG 13 -mock, PG 13 -Bcl-2, or CMV-Bcl-2 plasmids, irradiated them 24 h later, and assessed luciferase activity after an additional 72 h. In the MDA-MB-231 cells, an increase in cell survival was observed only for those cells that had been transfected with the CMV-Bcl-2 plasmid (Po0.01 relative to PG 13 -mock or PG 13 -Bcl-2) (Figure 4a ). By contrast, in the NIH 3T3 cells, transfection with PG 13 -Bcl-2 or CMV-Bcl-2 led to improved survival (Po0.05) (Figure 4a ). To confirm whether this improvement in survival resulted from a reduction in apoptosis, we assessed apoptotic cells by using a plasmid encoding the GFP and annexin V-PE staining. MDA-MB-231 cells and NIH 3T3 cells were transfected with GFP and with PG 13 -mock or PG 13 -Bcl-2 
PG 13 -Bcl-2 Plasmids induced Bcl-2 protein in mice lung
To confirm that Bcl-2 protein is induced by PG 13 -Bcl-2 in in vivo, female NCR mice were injected DOTAP, LPD-PG 13 -mock, LPD-PG 13 -Bcl-2, or LPD-CMV-Bcl-2 via a tail vein. The mice were killed at 24 h after irradiation, and their lungs were removed. We used immunohistochemical analysis to detect Bcl-2 protein expression in mice lung. As expected, Bcl-2 protein was expressed only in the lung from mice treated with LPD-PG 13 -Bcl-2 or LPD-CMV-Bcl-2 ( Figure 5 ).
Discussion
This study was undertaken to explore the hypothesis that radiation-induced toxicity results from apoptosis of normal cells, with the goal of developing a therapeutic plasmid with which to express antiapoptotic genes in normal cells. Here, we showed that transfection with Bcl-2 led to resistance to radiation-induced cytotoxicity as compared with untransfected parental cells. These results were consistent with the observation that overexpression of Bcl-2 can inhibit apoptosis for up to 72 h after irradiation. 7, 15, 16 Bcl-2 is known to participate in many functions required for initiating and propagating early apoptotic processes. Bcl-2 not only suppresses p53-mediated apoptosis but also interferes with p53 activity, thereby reducing the generation of early proapoptotic signals. 17 Bcl-2 overexpression also blocks apoptosis through an antioxidant pathway by raising total cellular glutathione levels. 18 In addition, Bcl-2 blocks the release of the proapoptotic molecule cytochrome-c from mitochondria, thereby inhibiting the activation of caspases induced by cytochrome-c. 19 Bcl-2 can also inactivate the proapoptotic protein Bax by forming heterodimers with it. 20 Aside from forming complexes Bax, Bcl-2 may also directly interfere with the opening of mitochondrial permeability transition pores. 21 Recently, Tepper et al.
22
suggested that Bcl-2 overexpression abrogated radiationinduced generation of ceramide and apoptosis. However, suppression of apoptosis does not necessarily lead to enhanced survival of normal cells. Here, we showed for the first time that Bcl-2-expressing clones of normal cells have enhanced clonogenic survival after irradiation. Few studies have analyzed the importance of the antiapoptotic Bcl-2 protein for clonogenic survival of cancer cells after irradiation. Strasser et al. 23 showed that overexpressed Bcl-2 strongly increased the clonogenic survival of lymphoid cells from p53-null mice after irradiation, and Bcl-2 had a comparable effect on clonogenic survival of murine LY lymphoma cells. 18, 24 In contrast, Kyprianou et al. 7 reported that overexpression Bcl-2 prevents radiation-induced toxicity H Itamochi et al of Bcl-2 in prostate cancer cell lines did not lead to an increase in radiation resistance; although Bcl-2 overexpression protected cells from radiation-induced apoptosis at 72 h, no significant difference was found in the clonogenic survival of those cells. Similarly, Bcl-2 overexpression had no effect on clonogenic survival of Jurkat cells after irradiation. 15, 16 The reason for these contradictory results may reflect the function of the p53 protein, which has critical roles in cell cycle transition, DNA repair, and apoptosis after irradiation. 25 Radiation causes single-and double-strand breaks in the sugar-phosphate backbone of the DNA molecule. The presence of double-strand breaks prompts the stabilization of p53 and activation of its transcription functions. p53 in turn either induces cell cycle arrest, thereby allowing time for DNA repair, or eliminates cells by triggering apoptosis. p53-induced apoptosis is thought to occur through its ability to induce proapoptotic Bcl-2 family members, including Bax, Bid, Noxa, and Puma. 26, 27 Normal mouse fibroblasts with wt p53 rapidly 28, 29 These results suggest that overexpressing Bcl-2 may reduce apoptosis in cells that have wt p53, which may translate into less cytotoxicity. Therefore, the therapeutic window for p53-mutated breast cancer may be narrow.
We found that wt p53 protein strongly upregulated the expression of Bcl-2 (delivered via PG 13 -Bcl-2) and functions as a radioprotectant by suppressing apoptosis. Increased cell viability and inhibition of apoptosis were observed only in NIH 3T3 cells that had been transfected with PG 13 -Bcl-2. Interestingly, in NIH 3T3 cells, transfection with PG 13 -Bcl-2 or CMV-Bcl-2 led to similar reductions in radiation-induced cytotoxicity. These results suggest that sufficient amounts of Bcl-2 are being expressed through PG 13 -Bcl-2 to block radiation-induced apoptosis. Ionizing radiation also induces a variable degree of apoptosis in tumor cells, with the extent of apoptosis correlated directly with antitumor efficacy of radiation therapy. 30, 31 Especially in normal cells, p53-mediated apoptosis is an important factor in determining sensitivity to ionizing radiation. 31 Moreover, p53 mutation status has to be examined before using the PG 13 -Bcl-2 plasmid, because this strategy can not be applied to patients carrying tumors with wt p53. However, p53-mutation is associated with increased risk of distant metastasis and poor prognosis in breast 11 and lung cancer, 32 and those patients may need to be received intensive treatment.
Preclinical studies indicated that LPD-mediated intravenous gene delivery have demonstrated effective transduction and gene product expression in vivo. 33, 34 Previous studies showed that tail vein injection of LDPluciferase to mice resulted in the luciferase gene expression in lung, heart, spleen, liver, and kidney with the highest expression in the lung. 33, 34 In this study, we confirmed that Bcl-2 protein was expressed in the lung from mice treated with LPD-PG 13 -Bcl-2 via a tail vein. These data suggest that PG 13 -Bcl-2 plasmid was effectively transferred to the mice lung and activated by wt p53. Further preclinical in vivo studies are needed to elucidate whether Bcl-2 protein expression in normal tissue could inhibit radiation-induced apoptosis and that translate into prevent radiation-induced toxicity.
We conclude that the normal cells used in this study respond to the genotoxic stress of radiation by rapidly upregulating the expression of wt p53, which binds to the PG sequences of the PG 13 -Bcl-2 plasmid and increases the transcriptional activity of Bcl-2. The ectopic expression of Bcl-2 reduced radiation-induced apoptosis in normal cells -but not in cancer cells -and hence may be the basis for a strategy to protect normal tissue from radiation-induced toxic effects.
